Gene transfer and the treatment of haematological malignancy

被引:9
作者
Brenner, MK [1 ]
机构
[1] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA
关键词
cytotoxic T cell; gene transfer; leukaemia;
D O I
10.1046/j.1365-2796.2001.00807.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Gene therapy offers an additional therapeutic modality for treating haematological malignancy. Because gene therapies could be truly specific for the malignancy, they should ultimately prove both safe and effective. We have far to go before this full potential is realized, but gene transfer strategies are already showing therapeutic promise. Gene transfer may be used to correct the genetic defect in the tumour, to render it more susceptible to conventional therapies, or the normal host cells more resistant, to induce or amplify an antitumour immune response, or simply as a means of tracking the tumour or cells used for treatment. This article describes examples of each approach and discusses future prospects for the field.
引用
收藏
页码:345 / 358
页数:14
相关论文
共 87 条
[1]   Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells [J].
Abonour, R ;
Williams, DA ;
Einhorn, L ;
Hall, KM ;
Chen, J ;
Coffman, J ;
Traycoff, CM ;
Bank, A ;
Kato, I ;
Ward, M ;
Williams, SD ;
Hromas, R ;
Robertson, MJ ;
Smith, FO ;
Woo, D ;
Mills, B ;
Srour, EF ;
Cornetta, K .
NATURE MEDICINE, 2000, 6 (06) :652-658
[2]  
ALLAY JA, 1997, BLOOD, V88, pA645
[3]   Should we purge? [J].
Bensinger, WI .
BONE MARROW TRANSPLANTATION, 1998, 21 (02) :113-115
[4]   IN-VITRO EVIDENCE THAT METABOLIC COOPERATION IS RESPONSIBLE FOR THE BYSTANDER EFFECT OBSERVED WITH HSV TK RETROVIRAL GENE-THERAPY [J].
BI, WL ;
PARYSEK, LM ;
WARNICK, R ;
STAMBROOK, PJ .
HUMAN GENE THERAPY, 1993, 4 (06) :725-731
[5]   T-LYMPHOCYTE-DIRECTED GENE-THERAPY FOR ADA(-) SCID - INITIAL TRIAL RESULTS AFTER 4 YEARS [J].
BLAESE, RM ;
CULVER, KW ;
MILLER, AD ;
CARTER, CS ;
FLEISHER, T ;
CLERICI, M ;
SHEARER, G ;
CHANG, L ;
CHIANG, YW ;
TOLSTOSHEV, P ;
GREENBLATT, JJ ;
ROSENBERG, SA ;
KLEIN, H ;
BERGER, M ;
MULLEN, CA ;
RAMSEY, WJ ;
MUUL, L ;
MORGAN, RA ;
ANDERSON, WF .
SCIENCE, 1995, 270 (5235) :475-480
[6]   HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia [J].
Bonini, C ;
Ferrari, G ;
Verzeletti, S ;
Servida, P ;
Zappone, E ;
Ruggieri, L ;
Ponzoni, M ;
Rossini, S ;
Mavilio, F ;
Traversari, C ;
Bordignon, C .
SCIENCE, 1997, 276 (5319) :1719-1724
[7]   IL-2 adenovector-transduced autologous tumor cells reduce antitumor immune responses in patients with neuroblastoma [J].
Bowman, L ;
Grossmann, M ;
Rill, D ;
Brown, M ;
Zhong, WY ;
Alexander, B ;
Leimig, T ;
Coustan-Smith, E ;
Campana, D ;
Jenkins, J ;
Woods, D ;
Kitchingman, G ;
Vanin, E ;
Brenner, M .
BLOOD, 1998, 92 (06) :1941-1949
[8]   Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma [J].
Bowman, LC ;
Grossmann, M ;
Rill, D ;
Brown, M ;
Zhong, WY ;
Alexander, B ;
Leimig, T ;
Coustan-Smith, E ;
Campana, D ;
Jenkins, J ;
Woods, D ;
Brenner, M .
HUMAN GENE THERAPY, 1998, 9 (09) :1303-1311
[9]   Gene marking [J].
Brenner, M .
HUMAN GENE THERAPY, 1996, 7 (16) :1927-1936
[10]   ASSESSMENT OF THE EFFICACY OF PURGING BY USING GENE MARKED AUTOLOGOUS MARROW TRANSPLANTATION FOR CHILDREN WITH AML IN FIRST COMPLETE REMISSION [J].
BRENNER, M ;
KRANCE, R ;
HESLOP, HE ;
SANTANA, V ;
IHLE, J ;
RIBEIRO, R ;
ROBERTS, WM ;
MAHMOUD, H ;
BOYETT, J ;
MOEN, RC ;
KLINGEMANN, HG .
HUMAN GENE THERAPY, 1994, 5 (04) :481-499